Log in with your email address username.


[Correspondence] Bivalirudin versus heparin use for patients undergoing PPCI

Adeel Shahzad and colleagues1 concluded that heparin, compared with bivalirudin, reduces the incidence of major adverse cardiovascular events (MACEs) in a setting of primary percutaneous coronary intervention without increasing the risk of bleeding complications. However, findings from this study1 do not accord with those from other multicentre randomised trials.2,3 In the study by Shahzad and colleagues,1 the incidence of overall MACE rates in the bivalirudin group was very high compared with other studies, but the rates reported between the other studies were comparable (table).